Mobilization of Leukemic Cells Using Plerixafor as Part of a Myeloablative Preparative Regimen for Patients with Acute Myelogenous Leukemia Undergoing Allografting: Assessment of Safety and Tolerability.

•All patients engrafted following hematopoietic cell transplantation (HCT).•Adverse events related to plerixafor were transient and not severe.•Plerixafor is safe to use with myeloablative allogeneic HCT for acute myelogenous leukemia.•Further investigation of outcomes in a larger cohort is warranted.